|
|
||||||||
1From the Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and the 2Department of Ophthalmology, Faculty of Medicine, Kagoshima University, Kagoshima, Japan.
PURPOSE. To investigate the functional properties and intracellular signaling of hyalocytes under platelet-derived growth factor (PDGF)rich conditions.
METHODS. The hyalocytes were isolated from bovine eyes and identified by immunocytochemistry and electron microscope. The expression of PDGF receptor
/ß and its phosphorylation in response to PDGF-BB was analyzed by Western blot analysis. PDGF-BBinduced proliferation and migration were evaluated by thymidine uptake and Boydens chemotaxis assay. The expression of the urokinase-type plasminogen activator (uPA) gene and the fibrinolytic activity were assessed by Northern blotting and fibrin zymography. An in vitro type I collagen gel contraction assay was performed to determine the effect of PDGF-BB on cellular contraction.
RESULTS. The hyalocytes were immunocytochemically positive for S-100 and negative for glial fibrillary acidic protein (GFAP) and cytokeratin, as previously described. The electron microscope demonstrated that hyalocytes possess lysosome-like granules, mitochondria, and micropinocytotic vesicles in their cytoplasm. The hyalocytes expressed PDGF receptor
and ß, both of which were immediately phosphorylated in response to PDGF-BB. PDGF-BB also activated p85 PI3-kinase, p44/p42 mitogen-activated protein (MAP) kinase and p38 MAP kinase. PDGF-BB induced thymidine uptake and migration in a concentration-dependent (010 ng/mL) manner. Inhibitors of the respective kinases prohibited PDGF-BBdependent thymidine uptake and migration with the exception of the p44/p42 MAP kinase inhibitor, which displayed no inhibitory effects on migration. PDGF-BB increased uPA gene expression and fibrinolytic activity. Collagen gel contraction observed under PDGF-BBrich conditions was not prohibited by the respective inhibitors investigated.
CONCLUSIONS. The hyalocytes demonstrated macrophage-like characteristics and may have both physiologic and pathologic roles, such as the maintenance of vitreous transparency through fibrinolytic activity and the pathogenesis of proliferative-vitreoretinal diseases through cellular proliferation and vitreous hyper-contraction.
This article has been cited by other articles:
![]() |
T. Kita, Y. Hata, R. Arita, S. Kawahara, M. Miura, S. Nakao, Y. Mochizuki, H. Enaida, Y. Goto, H. Shimokawa, et al. Role of TGF-{beta} in proliferative vitreoretinal diseases and ROCK as a therapeutic target PNAS, November 11, 2008; 105(45): 17504 - 17509. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Hata, Y Sassa, T Kita, M Miura, K Kano, S Kawahara, R Arita, S Nakao, J L Shih, and T Ishibashi Vascular endothelial growth factor expression by hyalocytes and its regulation by glucocorticoid Br. J. Ophthalmol., November 1, 2008; 92(11): 1540 - 1544. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kawahara, Y. Hata, T. Kita, R. Arita, M. Miura, S. Nakao, Y. Mochizuki, H. Enaida, T. Kagimoto, Y. Goto, et al. Potent Inhibition of Cicatricial Contraction in Proliferative Vitreoretinal Diseases by Statins Diabetes, October 1, 2008; 57(10): 2784 - 2793. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Kawahara, Y. Hata, M. Miura, T. Kita, A. Sengoku, S. Nakao, Y. Mochizuki, H. Enaida, A. Ueno, A. Hafezi-Moghadam, et al. Intracellular Events in Retinal Glial Cells Exposed to ICG and BBG Invest. Ophthalmol. Vis. Sci., October 1, 2007; 48(10): 4426 - 4432. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kita, Y. Hata, M. Miura, S. Kawahara, S. Nakao, and T. Ishibashi Functional Characteristics of Connective Tissue Growth Factor on Vitreoretinal Cells Diabetes, May 1, 2007; 56(5): 1421 - 1428. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kita, Y. Hata, K. Kano, M. Miura, S. Nakao, Y. Noda, H. Shimokawa, and T. Ishibashi Transforming Growth Factor-{beta}2 and Connective Tissue Growth Factor in Proliferative Vitreoretinal Diseases: Possible Involvement of Hyalocytes and Therapeutic Potential of Rho Kinase Inhibitor Diabetes, January 1, 2007; 56(1): 231 - 238. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Hirayama, Y. Hata, Y. Noda, M. Miura, I. Yamanaka, H. Shimokawa, and T. Ishibashi The Involvement of the Rho-Kinase Pathway and Its Regulation in Cytokine-Induced Collagen Gel Contraction by Hyalocytes Invest. Ophthalmol. Vis. Sci., November 1, 2004; 45(11): 3896 - 3903. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |